Regional Occupational Therapy Groups Are Quietly Selling to PE Rollups

Occupational therapy practices built over decades by clinicians who wanted to run their own shops are now among the most actively targeted businesses in healthcare private equity. The deals are mostly quiet, the sellers are often exhausted, and the buyers know exactly what they are getting.

Why OT Groups Became a PE Target

Private equity’s appetite for healthcare services has been well documented in specialties like dermatology, ophthalmology, and orthopedics. Occupational therapy took longer to attract serious rollup interest, largely because the practices tend to be smaller, the reimbursement mix is less glamorous, and the operational complexity of managing therapy across pediatric, adult, and geriatric populations made standardization harder to pitch to investors. That window has mostly closed now. PE firms that have already consolidated physical therapy networks are looking at OT as an adjacent play with similar margin logic and far less competitive pressure on acquisition pricing.

The business case is straightforward enough. Occupational therapy generates steady, recurring revenue tied to insurance reimbursement and, increasingly, school district contracts and early intervention programs funded by state agencies. Those revenue streams are not flashy, but they are predictable in ways that surgical specialties often are not. A well-run regional OT group with a dozen locations, strong therapist retention, and diversified payer mix looks attractive to a PE firm building a platform precisely because it is boring – steady utilization, limited seasonality, and patient populations that tend to need ongoing care rather than a single episode.

The current moment is also shaped by a specific generational dynamic. Many of the OT practice owners now fielding acquisition calls built their businesses in the 1990s and early 2000s, often after working as staff therapists and deciding to go independent. They are now in their late fifties or sixties, their children have not gone into occupational therapy, and a sale to a PE-backed platform represents the only realistic liquidity event after years of building something without a natural succession path. That combination – motivated sellers without alternatives, stable cash flows, fragmented geography – is precisely what rollup buyers look for.

Reimbursement pressure adds another layer. Medicare payment rates for therapy services have faced sustained compression, and smaller independent groups lack the billing infrastructure and contract negotiation leverage to push back effectively. Joining a larger platform promises access to better payer contracts, centralized billing, and administrative support that the solo or small-group owner cannot afford to build alone. For some sellers, the pitch is genuinely appealing before they read the fine print on earnout structures and clinical autonomy clauses.

How the Deals Actually Work

The typical OT rollup acquisition follows a structure that has become standard across healthcare PE. A platform company – usually already backed by a private equity sponsor and built around an initial “anchor” acquisition – approaches regional groups through a combination of direct outreach and healthcare-focused M&A brokers. The initial conversations are framed around partnership and growth rather than acquisition, and sellers are frequently told they will retain meaningful operational control after the transaction closes. That framing often does not survive contact with the actual purchase agreement.

Purchase prices in the current market tend to be expressed as multiples of EBITDA, and the headline numbers – often in the range of six to nine times for well-performing regional groups – can sound substantial to owners who have never sold a business before. What matters more than the headline multiple is how EBITDA gets calculated. PE buyers apply aggressive add-backs, normalize out owner compensation, and sometimes capitalize pre-close investments in ways that inflate the base number and reduce the real multiple the seller receives. The rollup math works because the acquiring platform expects to exit at a higher multiple than it paid for individual practices, capturing what the industry calls multiple arbitrage.

Earnout provisions are where many OT sellers encounter friction they did not anticipate. A portion of the purchase price – sometimes a significant portion – is tied to hitting post-close revenue or EBITDA targets. Those targets are set at close, before the buyer has made any operational changes, and achieving them while simultaneously absorbing the disruption of integration, staff retraining, and new billing systems is harder than the acquisition pitch suggested. This pattern is similar enough across healthcare services sectors that it has generated serious regulatory scrutiny in adjacent markets. The same structural tensions that created problems in hospice staffing, where per-visit contract economics got squeezed after ownership changes, surface here too.

Therapist retention after acquisition is the operational variable that PE firms consistently underestimate. Occupational therapists, particularly those who have worked in a clinician-owned practice, place real value on the culture and clinical flexibility that independent ownership provides. When that ownership changes and new policies arrive around documentation requirements, productivity targets, and patient volume expectations, turnover follows. A practice that sold at a premium partly because of its low therapist turnover can find itself in a staffing crisis within eighteen months of closing, which pressures the revenue projections the earnout was built on.

Geographic concentration creates another risk that is specific to OT rollups. Unlike national physician networks that can absorb localized disruption, a regional OT group often depends on relationships with a specific set of referring pediatricians, school districts, and hospital discharge planners. Those referral relationships were built by the founding clinician over years. When a known owner sells to a faceless holding company, some referring partners quietly begin diversifying where they send patients. The platform may not notice this erosion quickly because it shows up gradually in referral volume data that gets buried in consolidated reporting.

What Comes After the Close

The PE investment horizon for most healthcare rollups runs five to seven years, ending in either a sale to a larger strategic buyer, a secondary sale to another PE firm, or in some cases a public listing. For OT platforms, the most likely exit is a secondary PE sale or absorption into a larger therapy services company. What that means for the original selling therapist – who may still be working in the practice under an employment agreement that came with the acquisition – is that their employer will change at least once more before any stable long-term ownership emerges. The clinical environment they sold into may look substantially different from what was pitched.

Some OT owners who have gone through the process describe the post-close experience in terms that the acquisition pitch did not prepare them for: productivity dashboards, corporate compliance training, new documentation platforms that do not talk to their existing systems, and a headquarters-level contact who handles their concerns but has no clinical background and limited decision-making authority. The autonomy that the pitch promised tends to contract as integration deepens. Whether that trade-off was worth the liquidity is a question each seller lands on differently – and a few who retained enough equity in the platform are watching closely to see whether the exit multiple actually materializes.